Free call 0800 52 00 161 / Existing patients: 0207 078 4868
Patient Portal
UK
Brasil Chile Deutschland España France International Italia Panamá Portugal Russia UK

50% off our Diagnostic Package

Book Now
IVI UK
    • Fertility diagnosis

      • The IVI Diagnostic Pack
      • MUMS² Pack
      • Fertility Assessments
      • Starting Fertility Treatment
    • ASSISTED REPRODUCTION

      • Intrauterine Insemination (IUI)
      • In Vitro Fertilisation (IVF)
      • Reciprocal IVF
      • Egg Donation
      • Preserving Fertility
    • OUR RESULTS

      • Success Rates
    • ANSWER YOUR QUESTIONS

      • Causes of Infertility
      • Your First Visit
      • Fertility Treatment After 40
      • Fertility Treatment for Single Women
      • Fertility treatment for LGBTQ+ couples
      • Endometriosis
      • Polycystic Ovary Syndrome (PCOS) Guide
      • Events on demand
    • ADVANCED TECHNIQUES

      • Intracytoplasmic Sperm Injection (ICSI)
      • EmbryoScope
      • Vitrification of oocytes
    • GENETIC TESTS

      • PGT-A / PGS
      • PGT-M / PGT-SR
  • Prices
    • UK

      • London
    • Donor Programme Overseas

      • Egg Donation Program in Spain
  • Services for NHS Patients
    • SPECIALISTS

      • Medical team
    • CONTENTS

      • Blog
      • The Language of fertility
      • Press room
      • Why Choose IVI
Make an appointment
  • Fertility diagnosis

    • The IVI Diagnostic Pack
    • MUMS² Pack
    • Fertility Assessments
    • Starting Fertility Treatment
  • ASSISTED REPRODUCTION

    • Intrauterine Insemination (IUI)
    • In Vitro Fertilisation (IVF)
    • Reciprocal IVF
    • Egg Donation
    • Preserving Fertility
  • OUR RESULTS

    • Success Rates
  • ANSWER YOUR QUESTIONS

    • Causes of Infertility
    • Your First Visit
    • Fertility Treatment After 40
    • Fertility Treatment for Single Women
    • Fertility treatment for LGBTQ+ couples
    • Endometriosis
    • Polycystic Ovary Syndrome (PCOS) Guide
    • Events on demand
  • ADVANCED TECHNIQUES

    • Intracytoplasmic Sperm Injection (ICSI)
    • EmbryoScope
    • Vitrification of oocytes
  • GENETIC TESTS

    • PGT-A / PGS
    • PGT-M / PGT-SR
Prices
  • UK

    • London
  • Donor Programme Overseas

    • Egg Donation Program in Spain
Services for NHS Patients
  • SPECIALISTS

    • Medical team
  • CONTENTS

    • Blog
    • The Language of fertility
    • Press room
    • Why Choose IVI
Free call
Request information

21 January 2019

The risk of men requiring fertility treatments increases by 9%

Home Press room The risk of men requiring fertility treatments increases by 9%
The risk of men requiring fertility treatments increases by 9%

  • This study received the Academic Award of the Society for Male Reproduction and Urology, presented at the last edition of the ASRM
  • The sample, taken from approximately 120,000 men, is the largest used to date in world scientific literature

Male infertility now represents half the cases treated by assisted reproduction clinics. This fact, together with the apparent decrease in the quality of semen in recent years, is the focus of this study as a starting point that triggers alerts regarding the evolution of male fertility.

The research “Total motile sperm count trend over time across two continents: evaluation of semen analyses from 119,972 infertile men”, led by Dr. Ashley Tiegs, IVI fellow, examined the total mobile sperm count (TMSC) – the most important parameter that predicts the probability of achieving a pregnancy – of 119,982 men treated in IVI clinics spread between Spain and New Jersey, from 2002 and 2017. In conclusion, this study shows that the proportion of men at risk of requiring fertility treatment has increased significantly in recent years, from 12.4% in 2004 to 21.3% in 2017. This represents a 9% growth in little more than a decade, a rather alarming evolution.

“We have a large amount of information related to infertile patients, which has allowed us to demonstrate, improving even the findings of previous studies, that this decrease in the seminal quality implies clinical connotations that have an evident effect on male fertility, which forces us to use more complex treatments to fulfil the reproductive desire of our patients, “explains Dr. Nicolás Garrido, director of the IVI Foundation and co-author of the study.

This work received the Academic Award of the Society for Male Reproduction and Urology, presented in the latest edition of the ASRM (American Society of Reproductive Medicine), held in Denver last October.

During her research, Dr. Tiegs divided the data obtained into three groups: men with TMSC greater than 15 million sperm, numbers that would not require a fertility treatment in themselves; men with TMSC between five and 15 million, who would be at risk of requiring a lower fertility treatment such as artificial insemination; and men with TMSC between zero and five million, which could require in vitro fertilization (IVF), possibly with intracytoplasmic sperm injection (ICSI), to achieve a pregnancy.

“This is the largest study sample to date, which gives this work remarkable scientific weight. This, together with the revolutionary results that it brings, opens up a large research gap, demonstrating with objective data, evidence that we have been observing for some time in consultation and that nobody had been able to confirm until today. Further to these results, it will be necessary to analyse in more detail the causes of this fact and the measures to be taken. We are convinced that any progress along these lines will help us to clarify some of the issues that most concern us about the factors that influence male infertility, “adds Dr. Garrido.

With these findings, indicating that men have an increased risk of requiring reproductive treatments to be parents, the mandatory question is: Why?

“There is a lot of research about the adverse effects of toxic lifestyle and constant exposure to negative environmental influences on sperm quality, but it is not yet known exactly how harmful these factors are. Given that the etiology of this declining trend of TMSC remains speculation, a continuous and more accurate study of these factors is required, which can negatively affect sperm quality”, concludes Dr. Garrido.

Share on social networks

twitter facebook

Share on social networks

twitter facebook

PRESS ROOM CONTACTS

  • Ricardo Pedrós
  • Email: press.uk@ivirma.com
  • Phone number: +44 (0) 7553 730514
  • 83 Wimpole Street, London W1G 9RQ

Request more information, no obligation

Sending

Thank you,

One of our agents will contact you shortly. Meanwhile, have a look at our Virtual Events on Demand, in which you can find exclusive content about the fertility treatments we offer.

Access the fertility days

Experts in fertility

  • Infertility Treatments
  • The IVI Diagnostic Pack
  • IVI London
  • FAQs

Learn about us

  • Corporate information
  • IVIRMA Global Education
  • IVIRMA Innovation
  • Jobs at IVI
  • Legal Notice
  • Cookies Policy
  • Complaints policy
  • Treatment Terms & Conditions
  • logo
  • logo
  • logo
  • logo
  • logo

Head Offices

  • Calle Colón 1, 4ª planta, 46004 Valencia. España.

London Clinic

  • 83 Wimpole Street W1G 9RQ - London